Immunotherapy Drugs Market: How Combination Therapies Are Giving Cancer Vaccines a New Role
The global immunotherapy drugs market was valued at USD 285.7 billion in 2025 and is projected to reach USD 676.0 billion by 2033, growing at an 11.4% CAGR from a 2026 base of USD 317.2 billion. Monoclonal antibodies account for 56.16% of drug-type revenue; cancer indications account for 88.42% of the market. North America leads with 41.8% share; Asia Pacific is the fastest-growing region at a projected 12.45% CAGR. What follows is a structured read of what's actually behind those numbers. Background: Why Cancer Absorbs Almost Nine in Ten Dollars Spent Here The World Health Organization's data on cancer's global burden — nearly 10 million deaths in a single reporting year, roughly one in six deaths worldwide — explains the sheer scale of the cancer segment, but it doesn't fully explain why immunotherapy specifically has captured 88.42% of indication-level revenue rather than that spend spreading more evenly across treatment modalities. The answer is clinical performa...